作者:Jiřı́ Moravec、Vladimı́r Kryštof、Jan Hanuš、Libor Havlı́ček、Daniela Moravcová、Květoslava Fuksová、Marek Kuzma、René Lenobel、Michal Otyepka、Miroslav Strnad
DOI:10.1016/s0960-894x(03)00632-2
日期:2003.9
Purine inhibitors of cyclin-dependent kinases attract attention as potential anticancer drugs because their first representative roscovitine recently entered clinical trials. Although well described in terms of structure-activity relationships, we still present here a novel modification of the purine scaffold influencing their inhibitory properties. The introduced C-8 substituents, however, lowered the CDK inhibitory activity of roscovitine, whereas the antiproliferative potential of several derivatives remained high. (C) 2003 Elsevier Ltd. All rights reserved.